Episode Details
Back to Episodes
SF Healthcare Week: Alumis' CEO Martin Babler walks us through the two successful phase 3 trials the company announced for its TYK2 last week
Published 8 months ago
Description
He discusses the TYK2 landscape and describes why Alumis believes TYK2 can be a broad class in immunology.